Stephen N Crooke1, Marguerite M Riggenbach1, Inna G Ovsyannikova1, Nathaniel D Warner2, Min-Hsin Chen3, Lijuan Hao3, Joseph P Icenogle3, Gregory A Poland1, Richard B Kennedy4. 1. Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA. 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. 3. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA. Electronic address: kennedy.rick@mayo.edu.
Abstract
BACKGROUND: While administration of the measles-mumps-rubella (MMR-II®) vaccine has been effective at preventing rubella infection in the United States, the durability of humoral immunity to the rubella component of MMR vaccine has not been widely studied among older adolescents and adults. METHODS: In this longitudinal study, we sought to assess the durability of rubella virus (RV)-specific humoral immunity in a healthy population (n = 98) of adolescents and young adults at two timepoints: ~7 and ~17 years after two doses of MMR-II® vaccination. Levels of circulating antibodies specific to RV were measured by ELISA and an immune-colorimetric neutralization assay. RV-specific memory B cell responses were also measured by ELISpot. RESULTS: Rubella-specific IgG antibody titers, neutralizing antibody titers, and memory B cell responses declined with increasing time since vaccination; however, these decreases were relatively moderate. Memory B cell responses exhibited a greater decline in men compared to women. CONCLUSIONS: Collectively, rubella-specific humoral immunity declines following vaccination, although subjects' antibody titers remain well above the currently recognized threshold for protective immunity. Clinical correlates of protection based on neutralizing antibody titer and memory B cell ELISpot response should be defined.
BACKGROUND: While administration of the measles-mumps-rubella (MMR-II®) vaccine has been effective at preventing rubella infection in the United States, the durability of humoral immunity to the rubella component of MMR vaccine has not been widely studied among older adolescents and adults. METHODS: In this longitudinal study, we sought to assess the durability of rubella virus (RV)-specific humoral immunity in a healthy population (n = 98) of adolescents and young adults at two timepoints: ~7 and ~17 years after two doses of MMR-II® vaccination. Levels of circulating antibodies specific to RV were measured by ELISA and an immune-colorimetric neutralization assay. RV-specific memory B cell responses were also measured by ELISpot. RESULTS:Rubella-specific IgG antibody titers, neutralizing antibody titers, and memory B cell responses declined with increasing time since vaccination; however, these decreases were relatively moderate. Memory B cell responses exhibited a greater decline in men compared to women. CONCLUSIONS: Collectively, rubella-specific humoral immunity declines following vaccination, although subjects' antibody titers remain well above the currently recognized threshold for protective immunity. Clinical correlates of protection based on neutralizing antibody titer and memory B cell ELISpot response should be defined.
Authors: Emma E Seagle; Robert A Bednarczyk; Tenisha Hill; Amy Parker Fiebelkorn; Carole J Hickman; Joseph P Icenogle; Edward A Belongia; Huong Q McLean Journal: Vaccine Date: 2018-01-06 Impact factor: 3.641
Authors: Mohammed Ata Ur Rasheed; Carole J Hickman; Marcia McGrew; Sun Bae Sowers; Sara Mercader; Amy Hopkins; Vickie Grimes; Tianwei Yu; Jens Wrammert; Mark J Mulligan; William J Bellini; Paul A Rota; Walter A Orenstein; Rafi Ahmed; Srilatha Edupuganti Journal: Proc Natl Acad Sci U S A Date: 2019-09-03 Impact factor: 12.779
Authors: Marguerite M Riggenbach; Iana H Haralambieva; Inna G Ovsyannikova; Daniel J Schaid; Gregory A Poland; Richard B Kennedy Journal: Clin Immunol Date: 2021-12-28 Impact factor: 3.969
Authors: Janna R Shapiro; Huifen Li; Rosemary Morgan; Yiyin Chen; Helen Kuo; Xiaoxuan Ning; Patrick Shea; Cunjin Wu; Katherine Merport; Rayna Saldanha; Suifeng Liu; Engle Abrams; Yan Chen; Denise C Kelly; Eileen Sheridan-Malone; Lan Wang; Scott L Zeger; Sabra L Klein; Sean X Leng Journal: NPJ Vaccines Date: 2021-12-09 Impact factor: 7.344